Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ERx is a putative membrane estrogen receptor identified via its associated gene transcription signature that is induced by estradiol independently of the classical nuclear and membrane estrogen receptors ERα, ERβ, and GPER. It was characterized using a membrane-impermeable estradiol conjugate (E2-BSA), in studies where classic ER antagonists and GPER antagonists were used to dissect out independent pathways. Little is known about the molecular identity, structure, or biological roles of ERx. There is no evidence it is targeted by approved drugs or is a validated therapeutic target. Much of the literature using "ERX" actually refers to ERX-11, a small molecule modulator of ERα function, which is unrelated to ERx as a distinct receptor.
Estradiol-induced gene transcription through a non-ERα/ERβ/GPER pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Membrane estrogen receptor (putative, ERx) (ERx).